Omecamtiv mecarbil treatment improves post-resuscitation cardiac function and neurological outcome in a rat model.

ABSTRACT:

Background

Myocardial dysfunction is a major cause of poor outcomes in the post-cardiac arrest period. Omecamtiv mecarbil (OM) is a selective small molecule activator of cardiac myosin that prolongs myocardial systole and increases stroke volume without apparent effects on myocardial oxygen demand. OM administration is safe and improves cardiac function in patients with acute heart failure. Whether OM improves post-resuscitation myocardial dysfunction remains unclear. This study investigated the effect of OM treatment on post-resuscitation myocardial dysfunction and outcomes.

Methods and results

Adult male rats were resuscitated after 9.5 min of asphyxia-induced cardiac arrest. OM and normal saline was continuously intravenously infused after return of spontaneous circulatio

SUBMITTER: Wu SN 

PROVIDER: S-EPMC8853579 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature